Detection of pegylated epoetin β in horse plasma after intravenous administration

Comparative Exercise Physiology

Volumn 6, Issue 3, 2009, Pages 105-108

  Catlin, D H ^a   Maylin, G A ^b   Benchaar, S ^a   Neades, S M ^a   Timmons, M S ^a   McKeever, K H ^c  

^a Anti Doping Research Inc   (United States)

^b Cornell University ^*  (United States)

^c The State University of New Jersey   (United States)

Author keywords

doping; erythropoietin; horse; methoxy polyethylene glycol epoetin ; Mircera ; recombinant human erythropoietin epoetin

Indexed keywords

EID: 85011523959     PISSN: 17552540     EISSN: 17552559     Source Type: Journal    
DOI: 10.1017/S1755254009990171     Document Type: Article

References (14)

1. Ekblom B (1996). Blood doping and erythropoietin. The effects of variation in hemoglobin concentration and other related factors on physical performance. The American Journal of Sports Medicine 24: S40–S42.
2. McKeever KH, Agans JM, Geiser S, Lorimer PJ and Maylin GA (2006). Low dose exogenous erythropoietin elicits an ergogenic effect in Standardbred horses. Equine Veterinary Journal, Supplement 36: 233–238.
3. Catlin DH and Hatton CK (2009). Abuse of recombinant erthropoietins by athletes. In: Elliott SG, Foote MA and Molineux G (eds) Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Molecular, Cellular, Preclinical, and Clinical Biology. 2nd edn. Basel: Birkhäuser.
4. Elliott S (2008). Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. British Journal of Pharmacology 154: 529–541.
5. Lasne F, Martin L, Martin JA and de Ceaurriz J (2009). Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control. Haematologica 94: 888–890.
6. Lasne F and de Ceaurriz J (2000). Recombinant erythropoietin in urine. Nature 405: 635.
7. Lasne F, Martin L, Crepin N and de Ceaurriz J (2002). Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Analytical Biochemistry 311: 119–126.
8. Lasne F (2001). Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. Journal of Immunological Methods 253: 125–131.
9. Catlin DH, Breidbach A, Elliott S and Glaspy J (2002). Comparison of isoelectric focusing patterns of darbepoetin alfa, recombinant human EPO, and endogenous EPO from human urine. Clinical Chemistry 48: 2057–2059.
10. Lasne F, Popot MA, Varlet-Marie E, Martin L, Martin JA, Bonnaire Y, et al(2005). Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. Journal of Analytical Toxicology 29: 835–837.
11. Sato F, Yamashita S, Kugo T, Hasegawa T, Mitsui I and Kijima-Suda I (2004). Nucleotide sequence of equine erythropoietin and characterization of region-specific antibodies. American Journal of Veterinary Research 65: 15–19.
12. Kearns CF, Lenhart JA and McKeever KH (2000). Cross-reactivity between human and erythropoietin antibody and horse erythropoietin. Electrophoresis 21: 1454–1457.
13. Lasne F, Martin L, Martin JA and de Ceaurriz J (2007). Isoelectric profiles of human erythropoietin are different in serum and urine. International Journal of Biological Macromolecules 41: 354–357.
14. Lamon S, Giraud S, Egli L, Smolander J, Jarsch M, Stubenrauch KG, et al(2009). A high-throughput test to detect C.E.R.A. doping in blood. Journal of Pharmaceutical and Biomedical analysis. doi:10.1016/jpba.2009.06.038.